The New York Eye & Ear Infirmary

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, The New York Eye & Ear Infirmary sits in the top decile of US sponsors by registered trial count (#1,137 of 15,742 sponsors by registered trial count).

12 total trials 1 currently recruiting 8 completed early-phase tilt top decile by trial count

The New York Eye & Ear Infirmary: 12 sponsored US clinical trials, 1 recruiting.

The New York Eye & Ear Infirmary sponsors 12 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 8 completed. 1 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Nasolabial Folds, with 1 trials.

Top-decile sponsor footprint

The New York Eye & Ear Infirmary ranks in the top decile of sponsors by registered trial count (#1,137 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 21/100

8 of 11 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (72.7%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

12 total, page 1 of 1

RECRUITING

To Study Ocular Outflow Dynamics of the Eye Using Intraoperative Tonographic Biometry and Assess Its Predictive Value in Improving Postoperative Outcomes.

NCT07425496
TERMINATED Phase 1

Safety and Efficacy of Anti-Oxidants and Anti-inflammatory Agents in Glaucoma and Diabetic Retinopathy

NCT02984813
TERMINATED Phase 2

The Effectiveness of Ologen® Collagen Matrix in Preventing Intraocular Pressure (IOP) Spikes After Ahmed Glaucoma Valve Surgery (AGV-FP7)

NCT02990143
COMPLETED Phase 3

Enhancing Hair Density With Platelet Rich Fibrin Matrix (PRFM)

NCT01590238
COMPLETED

Outcomes and Patient Experience After Soft Tissue Dermal Filler Injections

NCT01034956
COMPLETED Phase 1

Evaluation of the Mechanism of Action of Platelet Rich Fibrin Matrix (PRFM) in Producing Skin Volume Augmentation

NCT00956020
COMPLETED Phase 1

Pilot Evaluation of Platelet Rich Fibrin Matrix (PRFM) for the Correction of Nasolabial Folds

NCT00874094
COMPLETED

Photographic Assessment of Eyebrow Position and Range of Motion

NCT00347308
TERMINATED Early Phase 1

DIM as a Treatment for Thyroid Disease

NCT01846364
COMPLETED

Comparison of a Spectral OCT/SLO With the Stratus OCT for Imaging Various Retinal Pathologies

NCT00408720
COMPLETED

Efficacy of the Bone-anchored Hearing Aid for Unilateral Deafness

NCT00201617
COMPLETED Phase 1

Treatment of Failing Blebs With Ranibizumab

NCT00570726

Phase Distribution

PhaseTrial count
Phase 1 5
Phase 2 1
Phase 3 1

Therapeutic Areas

Nasolabial Folds 1
Glaucoma 1
Cataract 1

What is open in the The New York Eye & Ear Infirmary pipeline

1 recruiting of 12 indexed (8% open); 8 completed (67%).

Phase mix: 1 late (III/IV) vs 6 early (I/II) (early-phase heavy).

Top condition: Nasolabial Folds (1 trial), 2 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

The New York Eye & Ear Infirmary: open-pipeline peers nationwide

Peers matched on 12 registered trials and 8% open enrollment, not the therapeutic-area sidebar.

The New York Eye & Ear Infirmary sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 10152025 0%5%10%15%20% Total trials Recruiting share The New York Eye & Ear InfirmaryAlachua Government ServicesAllergy TherapeuticsAmpio Pharmaceuticals.AngiodynamicsAcrotech BiopharmaAtlanta VA Medical CenterBeacon TherapeuticsBoston VA Research Institute
The New York Eye & Ear Infirmary sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

The New York Eye & Ear Infirmary sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 12 trials (± recruiting share)

Sponsors near 8% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this The New York Eye & Ear Infirmary page

12 registered trials is a research-attention snapshot, not an endorsement of The New York Eye & Ear Infirmary or any single study.

  • 1 of The New York Eye & Ear Infirmary's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Nasolabial Folds is the condition The New York Eye & Ear Infirmary studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Nasolabial Folds trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

The New York Eye & Ear Infirmary pipeline card: 12 registered trials from official public datasets.Report a data error.